Carbaglu
What Carbaglu is used for
Carbaglu is indicated in treatment of: hyperammonaemia due to N-acetylglutamate-synthase primary deficiency; hyperammonaemia due to isovaleric acidaemia; hyperammonaemia due to methymalonic acidaemia; hyperammonaemia due to propionic acidaemia.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Carbaglu
- Active substance
- carglumic acid
- Disease area
- Amino Acid Metabolism, Inborn Errors; Propionic Acidemia
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AA05
- Marketing authorisation holder
- Recordati Rare Diseases
- Authorised in the EU since
- 2003
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Carbaglu used for?
Carbaglu is indicated in treatment of: hyperammonaemia due to N-acetylglutamate-synthase primary deficiency; hyperammonaemia due to isovaleric acidaemia; hyperammonaemia due to methymalonic acidaemia; hyperammonaemia due to propionic acidaemia.
What is the active substance in Carbaglu?
Carbaglu contains carglumic acid.
Who makes Carbaglu?
The EU marketing authorisation holder is Recordati Rare Diseases.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU